Biology | Free Full-Text | Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
New targets for the development of a drug treatment for obesity and type 2 diabetes
Tirzepatide (Mounjaro)
Metabolic actions of GLP-1 and GIP on key target tissues. | Download Scientific Diagram
Frontiers | Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update - Nauck - 2021 - Diabetes, Obesity and Metabolism - Wiley Online Library
Diabetes drugs that protect pancreatic β cells
FDA Approves Mounjaro, a Novel Once-a-Week Medication to Treat Type 2 Diabetes | Everyday Health
Inkretinmimetika – Wikipedia
New Diabetes Medications, Technologies You Should Know
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY
Mechanism of action for GIP, GLP-1 analogues and DPP4 inhibitors in... | Download Scientific Diagram
How May GIP Enhance the Therapeutic Efficacy of GLP-1?: Trends in Endocrinology & Metabolism
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis | springermedizin.de
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update - Nauck - 2021 - Diabetes, Obesity and Metabolism - Wiley Online Library
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial - The Lancet
Total Glucose-dependent Insulinotropic Peptide (GIP) ELISA, 27203 (RUO) | Human Total GIP (Gastric Inhibitory Polypeptide) Competitive Enzyme-linked Immune-sorbent Assay Kit IBL-America
Impressive weight loss data for Lilly's dual GIP and GLP-1 diabetes candidate
GLP-1R and Diabetes
In vivo drug discovery for increasing incretin-expressing cells in diabetes
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes | Pharmacological Reviews
Biology | Free Full-Text | Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary ...
Intracellular actions of GIP and GLP-1 on the-cell. Several cellular... | Download Scientific Diagram
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY
